Seres Therapeutics
www.serestherapeutics.com
www.serescdiffstudy.com
617-945-9626 EXT. 304
email: clinicalstudies@serestherapeutics.com

ECOSPOR III Research Study For Adults With Recurrent *Clostridium difficile* infection (CDI)

Seres Therapeutics has some very exciting treatment-related news!

Seres Therapeutics is a leading microbiome therapeutics biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The human microbiome is made up of trillions of microbes that live in your body that normally protect you from potential bacterial invaders like *C. difficile* (i.e., "*C diff*"). But antibiotics can harm the good bacteria that live in the gut microbiome leading to debilitating diarrhea caused by *C. diff*.

Seres recently reported positive topline results from its Phase 3 ECOSPOR III study evaluating SER-109 for multiply recurrent *C. diff.* SER-109 is an investigational, oral, biologically-derived microbiome therapeutic designed to prevent recurrence of *C diff* in adults with history of recurrence. SER-109 is a community of bacterial spores purified from stool of healthy human donors and manufactured to inactivate and remove potential pathogens. In recognition of the unmet need for effective therapies for this debilitating recurrent disease which affects thousands of patients in the United States, the FDA has granted SER-109 both Breakthrough Therapy and Orphan Drug designations.

The Phase 3 study's efficacy results showed that the risk of disease recurrence was reduced by 73% in patients on the SER-109 treatment arm compared to those on the placebo arm.

Based on these results, Seres has initiated an open-label study in which all subjects will receive SER-109. Furthermore, you may qualify for the study even if this is only your first recurrence. If you have any questions about Seres's clinical trials, please contact us at:

Email: **clinicalstudies@serestherapeutics.com**
Phone: **617-945-9626, extension 304**
Company Web Site: *www.serestherapeutics.com*
Clinical Study Web Site: *www.serescdiffstudy.com*

We are deeply grateful to Nancy Caralla and the C diff Foundation for ongoing support of our drug development program and to the patients who took part in all our clinical trials. We couldn't have done it without you!